Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
Clinical trial NCT06780839 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06780839
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-15
- Primary completion
- 2029-01-15
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.